Tom Cornelissen, PhD, reMYND Science Director Contract Research:
“At reMYND's Contract Research Organization (CRO), we specialize in conducting efficacy and proof of concept studies using mouse models for Alzheimer's and Parkinson's disease. In our search for innovation, we have integrated Amytracker 520 from Ebba Biotech into our research protocols, and the results have been exceptional.
Amytracker 520 has significantly enhanced our ability to detect and analyse key pathological features in brain tissue. Specifically, we have successfully identified amyloid plaques, Tau tangles, Lewy body-like inclusions, and alpha-synuclein preformed fibrils (PFFs, which were administered stereotactically). The specificity of the stain, combined with a high signal-to-noise ratio, ensures that our findings are both accurate and reliable (find out more HERE).
Furthermore, the narrow spectrum of Amytracker 520 makes it an excellent choice for co-staining applications, allowing us to achieve comprehensive and detailed imaging results. This will be invaluable for our clients to advance the understanding of the underlying mechanisms of neurodegenerative diseases and in the development of potential therapeutic strategies.
Overall, Amytracker 520 has proven to become a critical tool in our research arsenal, and we highly recommend it to other researchers in the field of neurodegenerative disease studies."
Tom Cornelissen (PhD), Science Director Contract Research, reMYND, Leuven, Belgium